A share price of Myriad Genetics, Inc. [MYGN] is currently trading at $24.26, up 1.93%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MYGN shares have gain 4.16% over the last week, with a monthly amount drifted -0.49%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Leerink Partners upgraded its rating to Outperform on May 08, 2024, and elevated its price target to $35. Wells Fargo started tracking the stock assigning a Equal Weight rating and suggested a price target of $20 on December 19, 2023. Guggenheim initiated its recommendation with a Buy and recommended $23 as its price target on December 14, 2023. Wolfe Research started tracking with a Outperform rating for this stock on December 13, 2023, and assigned it a price target of $28.
Myriad Genetics, Inc. experienced fluctuations in its stock price throughout the past year between $13.82 and $25.95. Currently, Wall Street analysts expect the stock to reach $24.33 within the next 12 months. Myriad Genetics, Inc. [NASDAQ: MYGN] shares were valued at $24.26 at the most recent close of the market. An investor can expect a potential return of 0.29% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
Trailing Twelve Months sales for Myriad Genetics, Inc. [NASDAQ:MYGN] were 774.20M which represents 11.59% growth. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.35 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.78 points at the first support level, and at 23.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.58, and for the 2nd resistance point, it is at 24.90.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Myriad Genetics, Inc. [NASDAQ:MYGN] is 1.99. Also, the Quick Ratio is 1.82, while the Cash Ratio stands at 0.36. Considering the valuation of this stock, the price to sales ratio is 2.84, the price to book ratio is 2.89.
Transactions by insiders
Recent insider trading involved SPIEGELMAN DANIEL K, Director, that happened on Jun 04 ’24 when 3788.0 shares were sold. Director, SPIEGELMAN DANIEL K completed a deal on Jun 03 ’24 to sell 3788.0 shares. Meanwhile, President and CEO DIAZ PAUL J sold 75000.0 shares on May 15 ’24.
